Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
CTMX logo CTMX
Upturn stock ratingUpturn stock rating
CTMX logo

CytomX Therapeutics Inc (CTMX)

Upturn stock ratingUpturn stock rating
$2.32
Last Close (24-hour delay)
Profit since last BUY190%
upturn advisory
Regular Buy
BUY since 34 days
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

06/20/2025: CTMX (3-star) is a STRONG-BUY. BUY since 34 days. Profits (190.00%). Updated daily EoD!

Upturn Star Rating

ratingratingratingratingrating

Moderate Performance

These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.

Analysis of Past Performance

Type Stock
Historic Profit 52.44%
Avg. Invested days 27
Today’s Advisory Regular Buy
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 3.0
Stock Returns Performance Upturn Returns Performance 3.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 06/20/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 332.42M USD
Price to earnings Ratio 4.4
1Y Target Price 5.5
Price to earnings Ratio 4.4
1Y Target Price 5.5
Volume (30-day avg) 8780344
Beta 2.12
52 Weeks Range 0.40 - 3.10
Updated Date 06/22/2025
52 Weeks Range 0.40 - 3.10
Updated Date 06/22/2025
Dividends yield (FY) -
Basic EPS (TTM) 0.48

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin 28.2%
Operating Margin (TTM) 44.43%

Management Effectiveness

Return on Assets (TTM) 15.87%
Return on Equity (TTM) -5475.03%

Valuation

Trailing PE 4.4
Forward PE 7.02
Enterprise Value 292978214
Price to Sales(TTM) 2.48
Enterprise Value 292978214
Price to Sales(TTM) 2.48
Enterprise Value to Revenue 1.99
Enterprise Value to EBITDA 7.78
Shares Outstanding 157544000
Shares Floating 60985977
Shares Outstanding 157544000
Shares Floating 60985977
Percent Insiders 0.83
Percent Institutions 51.04

Analyst Ratings

Rating 4.17
Target Price 5.5
Buy 3
Strong Buy 2
Buy 3
Strong Buy 2
Hold 1
Sell -
Strong Sell -
Strong Sell -

ai summary icon Upturn AI SWOT

CytomX Therapeutics Inc

stock logo

Company Overview

overview logo History and Background

CytomX Therapeutics Inc. was founded in 2008 and is focused on developing probody therapeutics, which are antibodies that are activated specifically in the tumor microenvironment. It has evolved from early-stage research to clinical trials and partnerships with major pharmaceutical companies.

business area logo Core Business Areas

  • Probody Therapeutics Development: CytomX's core business is the discovery and development of probody therapeutics. These are designed to be inactive until they reach the tumor microenvironment, reducing off-target effects and improving safety.
  • Partnerships and Licensing: CytomX also generates revenue through partnerships and licensing agreements with pharmaceutical companies to co-develop and commercialize their probody therapeutics.

leadership logo Leadership and Structure

The leadership team includes Sean McCarthy (Chairman and CEO). The organizational structure is typical of a biotech company, with departments focused on research, development, clinical trials, and business development.

Top Products and Market Share

overview logo Key Offerings

  • CX-2029: CX-2029, a Probody drug conjugate (PDC) targeting CD71, is in clinical development. Market share data is unavailable due to its developmental stage, however the global drug conjugates market is dominated by Roche (RHHBY), Seagen (SGEN), and Immunomedics (acquired by Gilead). The market size for ADCs (antibody-drug conjugates) are expected to grow, but Probody drugs are a small segment of this.
  • CX-904: CX-904, is a conditionally activated bispecific T-cell engager targeting EGFR and CD3. It is designed to activate T cells within the tumor microenvironment to kill cancer cells. Competitors include Regeneron (REGN) and Amgen (AMGN) who also are designing T-Cell engagers. There is no revenue or Market Share data associated with this product since it is in clinical trial phases.

Market Dynamics

industry overview logo Industry Overview

The biopharmaceutical industry is highly competitive and research-intensive. Focus on oncology and innovative drug delivery systems are key trends.

Positioning

CytomX is a pioneer in the probody therapeutics field, aiming to improve cancer treatment with safer and more effective therapies. Their competitive advantage lies in their probody technology platform.

Total Addressable Market (TAM)

The TAM for cancer therapies is enormous, projected to be hundreds of billions of dollars. CytomX is positioned to capture a portion of this market through its probody platform, specifically targeting tumors with specific activators.

Upturn SWOT Analysis

Strengths

  • Probody technology platform
  • Strategic partnerships with major pharmaceutical companies
  • Focus on innovative cancer therapies
  • Experienced management team

Weaknesses

  • Reliance on research and development
  • Clinical trial risks
  • High cash burn rate
  • Limited commercialized products

Opportunities

  • Expansion of probody platform to other disease areas
  • Further partnerships and licensing agreements
  • Positive clinical trial results
  • Increasing demand for targeted cancer therapies

Threats

  • Competition from other cancer therapies
  • Regulatory hurdles
  • Failure of clinical trials
  • Patent expirations

Competitors and Market Share

competitor logo Key Competitors

  • RHHBY
  • MRK
  • BMY
  • LLY
  • AZN

Competitive Landscape

CytomX faces competition from established pharmaceutical companies and biotech firms in the cancer therapy market. Their probody technology offers a unique approach, but they need to demonstrate clinical efficacy and safety to gain market share.

Major Acquisitions

Growth Trajectory and Initiatives

Historical Growth: CytomX's historical growth is characterized by progress in research and development and the establishment of partnerships.

Future Projections: Future growth depends on the success of clinical trials and the commercialization of probody therapeutics.

Recent Initiatives: Recent initiatives include advancing clinical trials for CX-2029 and CX-904, as well as securing new partnerships.

Summary

CytomX is a biotech company with a promising probody technology platform for cancer therapies. It faces significant clinical trial risks and competition from larger pharmaceutical companies. Success hinges on favorable clinical trial outcomes and strategic partnerships. While innovative, the company needs to watch out for potential regulatory hurdles and competition.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company website
  • SEC filings
  • Analyst reports
  • Industry publications

Disclaimers:

The data and analysis provided are for informational purposes only and should not be considered investment advice. Investment decisions should be based on individual research and consultation with a financial advisor.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About CytomX Therapeutics Inc

Exchange NASDAQ
Headquaters South San Francisco, CA, United States
IPO Launch date 2015-10-08
Chairman & CEO Dr. Sean A. McCarthy DPHIL
Sector Healthcare
Industry Biotechnology
Full time employees 119
Full time employees 119

CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company that focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna; and clinical trial collaboration and supply agreement with Merck for the evaluation of CX-801 in combination with anti-PD-1 therapy, KEYTRUDA (pembrolizumab). The company was founded in 2008 and is based in South San Francisco, California.